Advertisement

Table of Contents

August 10, 2017; 130 (6)

INSIDE BLOOD COMMENTARIES

  • Hitting the target in IDH2 mutant AML
    Bas J. Wouters
  • Prevalent premalignancy
    Adam S. Sperling and Benjamin L. Ebert
  • Let's give BACH2 a breath of fresh air
    Francesco Bertoni

PERSPECTIVE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane de Botton and Martin S. Tallman
  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    Michael D. Amatangelo, Lynn Quek, Alan Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A. Bernard, Bin Wu, Katharine E. Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard-Lacronique, Anjan Thakurta, Paresh Vyas and Ross L. Levine

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

  • JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
    Riikka Karjalainen, Tea Pemovska, Mihaela Popa, Minxia Liu, Komal K. Javarappa, Muntasir M. Majumder, Bhagwan Yadav, David Tamborero, Jing Tang, Dmitrii Bychkov, Mika Kontro, Alun Parsons, Minna Suvela, Mireia Mayoral Safont, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Emmet McCormack, Bjørn T. Gjertsen, Krister Wennerberg, Jonathan Knowles and Caroline A. Heckman

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

LETTERS TO BLOOD

BLOOD WORK